Derma Sciences, Inc. is a global medical device / pharmaceutical company focused on wound care. Over the past 3 years, we have successfully launched several novel advanced wound care products. We also have a drug in development for dermal repair and scar prevention / reduction. Another key part of our business is the OEM / private labeling of a full line of commodity wound care dressings. In all, we are a strong wound care company – growing in our current markets and expanding internationally.
More about Derma Sciences
DSC127 is a patented analog of a naturally occurring peptide, Angiotensin. In multiple pre-clinical animal models, it has been shown to increase keratinocyte proliferation, increase extracellular matrix production, and increase vascularization. Additionally, histological examination has shown that DSC127 accelerated collagen deposition six-fold. All these help to accelerate dermal tissue repair. The drug is currently in a Phase II Diabetic Ulcer study.